ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BDSX vs TLSI // RSI-14 & 200D SMA MOMENTUM

Biodesix Inc. (NASDAQ) VS. TriSalus Life Sciences Inc. (NASDAQ) • 15-METRIC TALLY: BDSX 4 — TLSI 2
▲ RSI-14 & 200D SMA MOMENTUM LEADER: BDSX
rsi-technicals
44.0
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BDSX VS. TLSI) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BDSX TLSI SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 84.60% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -9.02% -7.96% -1.06 TLSI /fcf-yield <GO>
Operating Margin -31.50% -59.70% +28.20 BDSX /operating-margins <GO>
Net Profit Margin -39.90% -60.00% +20.10 BDSX /net-margins <GO>
Revenue Growth (YoY) 24.10% 53.40% -29.30 TLSI /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 4/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 44.0 38.4 +5.52 BDSX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $260.8M $237.7M $23.1M BDSX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BDSX REV TLSI REV BDSX GROSS % TLSI GROSS % BDSX FCF TLSI FCF
FY 2025 $88.5M $45.2M — 84.6% -$23.5M -$18.9M
FY 2024 $71.3M $29.4M — 86.1% -$51.9M -$41.2M
FY 2023 $49.1M $18.5M — — -$22.9M -$50.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BDSX // BETA —
TLSI // BETA —